IGF::OT::IGF GENE THERAPY RESOURCE PROGRAM (GTRP) LENTIVIRUS VECTOR PRODUCTION CORE LABORATORY FOR DR. YUPO MA RSA 1285, FEBRUARY 16, 2017 THROUGH MAY 31, 2017.

慢病毒载体生产核心实验室合同涉及根据食品和药物管理局(FDA)定义的良好制造规范(GMP)以及适用的州和联邦法规生产可扩展的临床级慢病毒载体，供NHBLI资助的研究人员使用。预计承包商将平均每年生产十二(12)批病媒，至少三(3)批用于临床研究或用于大型动物模型的安全性和有效性/剂量/药理学/毒理学测试。

The Lentiviral vector production core laboratory contract involves production of scalable clinical grade Lentiviral vectors, in accordance with Good Manufacturing Practices (GMP), as defined by the Food and Drug Administration (FDA), and applicable State and Federal regulations, for use by NHBLI funded investigators. It is expected that the contractor will produce an average of Twelve (12) vector batches per year for a minimum of three (3) batches for clinical studies or for safety and efficacy/dose/pharmacology/toxicology testing with large animal models.